New study: simple scan and blood test may reveal who benefits from melanoma immunotherapy
NCT ID NCT06199713
First seen Feb 02, 2026 · Last updated Jun 23, 2026 · Updated 17 times
Summary
This study looks at 24 people with advanced melanoma who are starting immunotherapy. Researchers will do a special PET/CT scan and a blood test for tumor DNA about 3-4 weeks after the first treatment. The goal is to see if these early tests can predict whether the immunotherapy is working or causing side effects. This is an observational study, meaning it does not test a new drug but aims to improve how doctors monitor treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Wisconsin Hospitals and Clinics (UWHC)
RECRUITINGMadison, Wisconsin, 53792, United States
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors quickly tell which melanoma patients are responding to immunotherapy and who might need a different approach.
What could go wrong
This is a very small, early-stage observational study (24 people). It is not testing a new treatment, so it won't directly change care. Results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.